TGA / PMDA / NMPA · Asia-Pacific
inhibitor — TGA / PMDA / NMPA regulatory status
inhibitor regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 171 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 090701 | Phase 3 | Takeda | NCT00851721 |
| 090701 | Phase 3 | Baxalta Innovations | NCT00851721 |
| APHP180596 | Phase 3 | PARItec | 2024-516849-39-01 |
| APHP211034 | Phase 3 | PARItec | 2024-511866-36-00 |
| APHP220763 | Phase 3 | PARItec | 2024-514952-34-00 |
| APHP220814 | Phase 3 | PARItec | 2023-504208-27-00 |
| Aromatase Inhibitors | Phase 3 | United Therapeutics Europe | NCT02338310 |
| BB2121-MM-003 | Phase 3 | Celgene | 2023-509848-10-00 |
| BO41423 | Phase 3 | HOFFMANN-LA ROCHE | 2023-506610-52-00 |
| C1 esterase inhibitor [human] (C1INH-nf) | Phase 3 | Takeda | NCT00289211, NCT00432510 |
| C1 esterase inhibitor [human] liquid | Phase 3 | Takeda | NCT02584959 |
| CONE-02 | Phase 3 | Maze Therapeutics | 2023-503507-29-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2024384453 | CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF | AU |
| 3886798 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | PT |
| 20260083736 | GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY | US |
| 20260060930 | New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases | US |
| 20260055120 | Bicyclic pyrimidinones as inhibitors of NOX4 | US |
| 20260008777 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | US |
| 20260001878 | SUBSTITUTED PYRROLOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | US |
| 2025333394 | Tiparp Inhibitor Compounds | US |
| 4640274 | LPAR1-INHIBITOREN | EP |
| 2025304535 | KAT6 Inhibitors | US |
| 12428379 | Acylsulfonamide KAT6A inhibitors | US |
| 12428395 | Heterocyclic compounds as kinase inhibitor and uses thereof | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of inhibitor?
inhibitor currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get inhibitor regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to inhibitor?
This spoke lists 171 published programs associated with inhibitor in our pipeline index.